Pasireotide (L-aspartate salt)

Pasireotide (SOM230) L-aspartate salt, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/[1][2].

Product Specifications

CAS Number

[396091-77-3]

Product Name Alternative

SOM230 L-aspartate

UNSPSC

12352209

Hazard Statement

H302, H315, H319, H335

Target

Somatostatin Receptor

Type

Peptides

Related Pathways

GPCR/G Protein; Neuronal Signaling

Field of Research

Cancer; Endocrinology

Assay Protocol

https://www.medchemexpress.com/pasireotide-l-aspartate-salt.html

Purity

98.0

Solubility

DMSO : 1 mg/mL (ultrasonic)

Smiles

N[C@@H](CC(O)=O)C(O)=O.NCCCC[C@@H](C(N[C@H]1CC2=CC=C(C=C2)OCC3=CC=CC=C3)=O)NC([C@H](NC([C@H](C4=CC=CC=C4)NC([C@H]5N(C([C@H](CC6=CC=CC=C6)NC1=O)=O)C[C@H](OC(NCCN)=O)C5)=O)=O)CC7=CNC8=C7C=CC=C8)=O

Molecular Formula

C62H73N11O13

Molecular Weight

1180.31

Precautions

H302, H315, H319, H335

References & Citations

[1]Lewis I, et, al. A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential. J Med Chem. 2003 Jun 5;46 (12) :2334-44.|[2]Quinn TJ, et, al. Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1 (MEN1) conditional knockout mouse model. Surgery. 2012 Dec;152 (6) :1068-77.|[3]Imhof AK, et, al. Differential antiinflammatory and antinociceptive effects of the somatostatin analogs octreotide and pasireotide in a mouse model of immune-mediated arthritis. Arthritis Rheum. 2011 Aug;63 (8) :2352-62.